Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Solid Tumor
• Metastatic Solid Tumor
• Prostate Cancer
• Pancreas Cancer
• Breast Cancer
• Ovarian Cancer
• Homologous Recombination Deficiency

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

MOMA Therapeutics

Last updated on ClinicalTrials.gov

July 23, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites